Clinical trials
Tumor clinical trials
Below are recruiting tumor clinical trials, each written for real people, not researchers. We’re tracking 3,362 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05068583Recruiting
Testing liquid blood samples in children with certain cancers
This trial studies “liquid biopsies,” which are blood tests, to help learn about specific cancers in children. It may help doctors monitor cancer and guide treatment using less invasive tests.
Los Angeles, CaliforniaAges 6 months+ - NCT06505395RecruitingPhase 2
Octreotide injection for advanced neuroendocrine tumors
This trial is testing an injectable medicine called octreotide for people with advanced neuroendocrine tumors of the digestive system or pancreas. It aims to see if the medicine can help control the tumor.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07759960Recruiting
Removing small rectal tumors with two endoscopic methods
This study compares two minimally invasive ways to remove small rectal neuroendocrine tumors (NETs), which are growths in the rectum that are usually not cancer. The goal is to find which method is safer and more effective with fewer side effects.
Guangzhou, GuangdongAges 18–75 - NCT07753499Recruiting
PET scan for recurrent or metastatic thyroid cancer
This study tests a new type of PET scan to find thyroid cancer that has come back or spread. It compares two tracers to see which one better shows the cancer, which may help doctors choose the right treatment.
Xiamen, FujianAges 18–90 - NCT07751042RecruitingPhase 1/Phase 2
Study of STX-003 with and without pembrolizumab for advanced solid tumors
This study tests an experimental drug called STX-1, given alone or with another drug that helps the immune system fight cancer. It is for people with advanced solid tumors, especially certain types of lung cancer or melanoma, who have already tried standard treatments.
Scottsdale, ArizonaAges 18 years+ - NCT07753226RecruitingPhase 1
Study of SI-B036 for advanced breast cancer and other solid tumors
This study tests a new drug called SI-B036 for people with advanced breast cancer or other solid tumors that have spread. The goal is to see if the drug is safe and to find the best dose.
Beijing, Beijing MunicipalityAges 18–75 - NCT07755826Recruiting
Repotrectinib safety study in Japanese children with NTRK fusion tumors
This study tracks the safety and effects of the drug repotrectinib in children aged 4 to under 18 with certain tumors that have a specific genetic change (NTRK fusion). The goal is to see how well the drug works in everyday medical practice in Japan.
Minato-ku, TokyoAges 4–17 - NCT06525298RecruitingPhase 1/Phase 2
Study of EIS-12656 for solid tumors with DNA repair defects
This trial tests a new drug, EIS-12656, alone or with other treatments, for solid tumors that have specific DNA repair problems called homologous recombination deficiency. It may be an option if your cancer has not responded to prior treatments.
Houston, TexasAges 18 years+ - NCT06590506Recruiting
Wearable health tracking for advanced solid tumor treatment
This trial studies how using a wearable device and smartphone app can help monitor your health during your first cancer treatment for advanced solid tumors. You will receive a known therapy (not a placebo), and the research team will collect real-world data to improve care.
A Coruña, A Coruña/ GaliciaAges 18 years+ - NCT06592417RecruitingPhase 1
Study of JSKN016 for advanced solid tumors
This trial tests a new drug called JSKN016 for people with advanced cancer that has not responded to other treatments. It focuses on certain lung and breast cancers with specific genetic markers.
Fuzhou, FujianAges 18 years+ - NCT06587022Recruiting
Planning radiation for spinal tumors
This trial tests a precise type of radiation (stereotactic radiotherapy) for spinal tumors or cancer that has spread to the spine. It aims to study how best to target the radiation to improve treatment while reducing side effects.
Beijing, Beijing MunicipalityAges 18–90 - NCT07749586RecruitingPhase 1/Phase 2
Study of ARV-6723 alone or with pembrolizumab for advanced solid tumors
This trial tests an experimental drug called ARV-6723, alone or with another drug called pembrolizumab, for people with advanced solid tumors that have not responded to other treatments. The goal is to see if these combinations can help shrink tumors or slow their growth.
New York, New YorkAges 18 years+ - NCT07744763RecruitingPhase 1/Phase 2
Study of SYS6041 for advanced solid tumors
This trial tests a new drug called SYS6041 for people with certain advanced cancers that have not responded to standard treatments. It targets a protein called FRα found on some tumor cells, which may help the drug attack the cancer more effectively.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06259552RecruitingPhase 1
Study of SPX-303 for advanced solid tumors
This trial tests a new drug called SPX-303, which is designed to help your immune system fight cancer cells. It is for people with advanced solid tumors that have not responded to other treatments.
Phoenix, ArizonaAges 18 years+ - NCT07741006Enrolling by invitationEarly Phase 1
PET imaging study for adults with solid tumors
This study tests a new PET imaging agent called [68Ga]Ga-ELI411 to help see tumors more clearly. It is for adults with solid tumors who are already scheduled for a standard PET scan, and may help doctors better understand and manage their cancer.
Wuhan, HubeiAges 18 years+ - NCT07743749Recruiting
MRI-based study to classify and grade kidney tumors
This study uses MRI scans to help doctors better identify the type and severity of kidney tumors. It may lead to more accurate diagnoses without needing extra tests.
BeijingAges 18 years+ - NCT07744074Recruiting
Carbon-ion radiation for large chest tumors
This trial tests a new type of radiation using carbon ions to treat large tumors in the chest that have come back or not responded to prior treatments. It aims to see if this therapy is safe and effective for people who have few options.
Hangzhou, ZhejiangAges 18 years+ - NCT06515626RecruitingEarly Phase 1
Modified t cells for multiple cancers
This trial tests a personalized cell therapy where your own immune cells are collected, modified to better attack cancer, and then returned to you. It is for people with various solid tumors and lymphomas whose cancer cells have specific markers.
Zhengzhou, HenanAges 18–75 - NCT06613295Recruiting
Spine cancer trial: Surgery plus radiation vs radiation alone
This trial compares two treatments for cancer that has spread to the spine: surgery followed by precise radiation versus radiation alone. It aims to see if adding surgery improves pain, movement, and quality of life.
AalstAges 18 years+ - NCT06615193RecruitingPhase 1
Testing a new drug for certain blood and solid tumors
This study tests a new drug, HDM2005, for people with relapsed or hard-to-treat B-cell lymphoma or advanced solid tumors. The goal is to see if it is safe and effective.
Zhengzhou, HenanAges 18 years+ - NCT07738172RecruitingPhase 3
Osimertinib with or without lung tumor surgery for EGFR-mutated non-small cell lung cancer
This study tests whether adding surgery to remove the main lung tumor improves outcomes for people with stage 4 lung cancer that has a specific EGFR mutation and only limited spread. If you qualify, you will take the targeted drug osimertinib for 12 weeks, and if the tumor responds, you may be randomly assigned to either continue the drug alone or have the main tumor surgically removed and then continue the drug.
Taipei, Taipei CityAges 18 years+ - NCT07734116RecruitingPhase 1/Phase 2
Nivolumab for solid tumors and epithelioid sarcoma
This trial tests a new immunotherapy drug (nivolumab) in children and adults with certain hard-to-treat solid tumors. It may help if standard treatments haven't worked or aren't an option.
Chiba, ChibaAges 12 years+ - NCT07730021RecruitingPhase 1/Phase 2
New drug for advanced solid tumors
This trial tests a new drug called ASP388B, given alone or with standard treatments, for people with certain advanced solid tumors that have stopped responding to therapy. It may help shrink tumors or slow their growth.
Lake Success, New YorkAges 18 years+ - NCT07728942RecruitingPhase 1
SLR-108 PET imaging study for metastatic solid tumors
This trial uses a special imaging agent called SLR-108 to take detailed PET scans of your cancer. It aims to see if this scan can help doctors better understand metastatic solid tumors that have grown after previous treatment.
Newport Beach, CaliforniaAges 18 years+
Hear when a new Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for tumor?
- Yes. Clin2 currently lists 3,362 recruiting tumor studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a tumor trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a tumor trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.